CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

And, if all goes well, over the next five years as well.

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...